- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Patent holdings for IPC class C07K 16/24
Total number of patents in this class: 6702
10-year publication summary
|
503
|
507
|
528
|
605
|
645
|
680
|
613
|
573
|
503
|
278
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Janssen Biotech, Inc. | 1555 |
241 |
| Novartis AG | 10849 |
213 |
| Abbvie Inc. | 1800 |
129 |
| Amgen Inc. | 4074 |
118 |
| Eli Lilly and Company | 3842 |
114 |
| Genentech, Inc. | 3976 |
107 |
| Regeneron Pharmaceuticals, Inc. | 4264 |
101 |
| MedImmune Limited | 617 |
97 |
| Sanofi | 4055 |
82 |
| Immatics Biotechnologies GmbH | 1157 |
76 |
| Ablynx N.V. | 398 |
68 |
| Hoffmann-La Roche Inc. | 3418 |
64 |
| Chugai Seiyaku Kabushiki Kaisha | 1355 |
62 |
| F. Hoffmann-La Roche AG | 7925 |
61 |
| ZymoGenetics, Inc. | 190 |
58 |
| Boehringer Ingelheim International GmbH | 4650 |
56 |
| The Regents of the University of California | 19918 |
51 |
| National University of Singapore | 2449 |
49 |
| Bristol-myers Squibb Company | 4898 |
48 |
| Cedars-Sinai Medical Center | 1156 |
47 |
| Other owners | 4860 |